Phaseline

Companies › Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC)

Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC): clinical trials, targets and expected readouts

1 active drug program in 3 registered trials: 2 Phase 2, 1 Phase 1; Neurology, Cardiovascular; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
18F-metaFluorobenzylguanidine (18F-mFBG)
PET radiopharmaceutical for myocardial sympathetic innervation imaging
–Phase 2Heart Failure; Parkinson Disease (PD); Cardiovascular DiseasesDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT0453519318F-metaFluorobenzylguanidine (18F-mFBG)Phase 1Cardiovascular DiseasesCardiovascularMar 2025
NCT0696562118F-metaFluorobenzylguanidine (18F-mFBG)Phase 2Heart FailureCardiovascularDec 2026
NCT0717628618F-metaFluorobenzylguanidine (18F-mFBG)Phase 2Parkinson Disease (PD)NeurologyDec 2026

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Ever Neuro Pharma AMO Pharma Translational Sciences Edgewise Therapeutics CSPC Mingfule Pharmaceutical (Guangzhou)

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.